Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Current Investments (2017 - 2026)

Cogent Biosciences' Cash & Current Investments history spans 10 years, with the latest figure at $866.4 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 252.67% to $866.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $866.4 million through Mar 2026, up 252.67% year-over-year, with the annual reading at $900.8 million for FY2025, 213.77% up from the prior year.
  • Cash & Current Investments came in at $866.4 million for Q1 2026, down from $900.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $900.8 million in Q4 2025 to a low of $141.8 million in Q3 2022.
  • The 5-year median for Cash & Current Investments is $287.1 million (2024), against an average of $354.0 million.
  • Year-over-year, Cash & Current Investments tumbled 43.62% in 2025 and then soared 252.67% in 2026.
  • Cogent Biosciences' Cash & Current Investments stood at $259.3 million in 2022, then increased by 2.48% to $265.7 million in 2023, then rose by 8.04% to $287.1 million in 2024, then surged by 213.77% to $900.8 million in 2025, then fell by 3.82% to $866.4 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Cash & Current Investments are $866.4 million (Q1 2026), $900.8 million (Q4 2025), and $390.9 million (Q3 2025).